Trial Profile
Hunter Outcome Survey: A Global, Multi-Center, Long-Term, Observational Registry of Patients With Hunter Syndrome (Mucopolysaccharidosis Type II, MPS II)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOS
- Sponsors Shire; Takeda
- 27 Feb 2023 Status changed from recruiting to completed.
- 07 Nov 2022 Planned End Date changed from 31 Oct 2022 to 16 Feb 2023.
- 07 Nov 2022 Planned primary completion date changed from 31 Oct 2022 to 16 Feb 2023.